Piramal
knowledge action care

October 27, 2014

Corporate Relationship Department,
BSE Limited
New Trading Wing,
Rotunda Building, P.J. Towers,
Dalal Street, Fort,
Mumbai- 400 001.

Fax No. 22723121 / 22721072
22722037

The Market Operations Department,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No.C/1, G.Block
Bandra-Kurla Complex, Bandra (E)
Mumbai- 400 051.

Fax No. 26598237 / 26598238

Subject: Errata - Unaudited financial results for the quarter and half year ended September 30, 2014 (declared vide our letter dated 21st October, 2014)

Reference: BSE Scrip Code – 500302, NSE Symbol - PEL

Dear Sir / Madam,

Further to our letter dated 21st October 2014 vide which the unaudited financial results for the quarter and half year ended September 30, 2014 (subject to limited review by the statutory auditors) were declared by the Company, we have noticed certain inadvertent errors in Point No. 2, "Segment Results" of the consolidated financial results, in the table showing the consolidated Segment Wise Revenue, Results and Capital Employed. The errors have been highlighted in italics and underline in the table below. However, we would like to state that there is no change in the main statement of consolidated financial results.

(Rs. in Lakhs)

2. Segment Results (Profit / (Loss) including Exceptional Items but before Tax, Finance Cost and Exchange Gain)	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for current period ended	Year to date figures for *current* year ended	Previous Year ended
	30/09/2014	30/06/2014	30/09/2013	30/09/2014	30/09/2013	31/03/2014
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
a. Pharmaceuticals manufacturing and services*	*(27,690)*	(7,498)	(3,839)	*(35,188)*	(8,447)	(16,248)
b. Financial services including strategic investments**	16,242	3,16,635	6,714	3,32,877	3,826	11,236
c. Information management	*(11,168)*	(615)	1,293	*(11,783)*	1,008	3,610
Total	**(22,616)**	**3,08,522**	**4,168**	**2,85,906**	**(3,613)**	**(1,402)**
Add : Exchange Gain, Net	(218)	2,876	8,731	2,658	20,132	19,849
Add: Unallocated Income	521	7,095	370	7,616	908	1,742
Less: Finance Cost (unallocated)	13,846	11,154	14,778	25,000	32,514	63,666
Total Profit / (Loss) Before Tax	**(36,159)**	**3,07,339**	**(1,509)**	**2,71,180**	**(15,088)**	**(43,477)**

Piramal
knowledge action care

The table bearing the corrected numbers is appended below

(Rs. in Lakhs)

2. Segment Results (Profit / (Loss) including Exceptional Items but before Tax, Finance Cost and Exchange Gain)	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for current period ended	Year to date figures for previous year ended	Previous Year ended
	30/09/2014	30/06/2014	30/09/2013	30/09/2014	30/09/2013	31/03/2014
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
a. Pharmaceuticals manufacturing and services*	(38,211)	(7,498)	(3,839)	(45,709)	(8,447)	(16,248)
b. Financial services including strategic investments**	16,242	3,16,635	6,714	3,32,877	3,826	11,236
c. Information management	(647)	(615)	1,293	(1,262)	1,008	3,610
Total	**(22,616)**	**3,08,522**	**4,168**	**2,85,906**	**(3,613)**	**(1,402)**
Add : Exchange Gain, Net	(218)	2,876	8,731	2,658	20,132	19,849
Add: Unallocated Income	521	7,095	370	7,616	908	1,742
Less: Finance Cost (unallocated)	13,846	11,154	14,778	25,000	32,514	63,666
Total Profit / (Loss) Before Tax	**(36,159)**	**3,07,339**	**(1,509)**	**2,71,180**	**(15,088)**	**(43,477)**

We regret the error on our part and inconvenience caused to the stakeholders. You are requested to kindly take the revised statement showing the consolidated segment results on record and disseminate this information to the investing public. The Company has put further checks and controls in place to ensure that such errors do not get repeated in the future.

Thanking you.

Yours truly

For **PIRAMAL ENTERPRISES LIMITED**

CHANDA MAKHIJA THADANI
ASSISTANT COMPANY SECRETARY